Mandate

VINGE ADVISED THE UNDERWRITERS IN RELATION TO NORDAX’S LISTING ON NASDAQ STOCKHOLM

June 22, 2015

Vinge advised Morgan Stanley & Co International plc, Carnegie Investment Bank AB (publ), Citigroup Global Markets Ltd and ABG Sundal Collier AB in relation to Nordax listing on Nasdaq Stockholm. Nordax’s principal shareholder is Vision Capital. A prospectus was published on 4 June 2015 and the first day of trading on Nasdaq Stockholm was on 17 June 2015. The price in the offering was set at SEK 45. The total value of the offering amounts to SEK 2.847 billion, assuming that the over-allotment option is exercised in full.

Nordax is a leading niche bank in the Nordic region providing unsecured consumer loans and deposit accounts to about 95,000 customers in Sweden, Norway, Finland, Denmark and Germany. As of 31 March 2015 lending to the general public amounted to SEK 10.3 billion and deposits amounted to SEK 6.5 billion.

Vinge’s team consisted mainly of responsible partner Charlotte Levin and associates Joakim Hagberg, Sabina Börjesson and Joel Wahlberg, and Axel Hedberg regarding regulatory questions.

Related

Vinge advises Isofol Medical AB (publ) in connection with its rights issue of units

Through the rights issue of units, consisting of shares and warrants, and the exercised over-allotment issue, Isofol will receive approximately SEK 84 million and may receive an additional maximum of approximately SEK 110 million upon exercise of all warrants at the highest subscription price.
August 01, 2025

Vinge advises Oncorena in connection with share issue

Vinge advises Oncorena Holding AB in connection with a share issue of approximately SEK 133 million.
July 30, 2025

Vinge advises Karl Hedin and minority owners on the sale of AB Karl Hedin Sågverk to Vida

Vinge has advised Karl Hedin and minority shareholders in connection with the sale of AB Karl Hedin Sågverk to Vida Aktiebolag (“Vida”).
July 24, 2025